<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1517">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141409</url>
  </required_header>
  <id_info>
    <org_study_id>11</org_study_id>
    <nct_id>NCT05141409</nct_id>
  </id_info>
  <brief_title>The COMBO CAD Study</brief_title>
  <acronym>COMBO-CAd</acronym>
  <official_title>The COMBO CAD Study: Characterization cOMparison Between twO CAD Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Implementation of clinical strategies based on optical diagnosis of &lt;5 mm colorectal polyps&#xD;
      may lead to a substantial saving of economic and financial resources [1,2] Despite this,&#xD;
      84.2% of European endoscopists reported not to use such strategies - also named as leave-in&#xD;
      situ and resect- and-discard - in their practice due to the fear of an incorrect optical&#xD;
      diagnosis [3].&#xD;
&#xD;
      Indeed, accuracy of optical diagnosis is operator-dependent, and values reported in the&#xD;
      community setting are below the safety thresholds proposed for its incorporation in clinical&#xD;
      practice [4,5].&#xD;
&#xD;
      Artificial intelligence (AI) is being increasingly explored in different domains of medicine,&#xD;
      particularly those entailing image analysis. As optical diagnosis involves subitaneous&#xD;
      processing of multiple images, searching for specific visual clues, and recognizing&#xD;
      well-defined visual patterns, AI systems has the potential to help endoscopists in&#xD;
      distinguish neoplastic from non-neoplastic polyps, making the characterization process more&#xD;
      reliable and objective. Computer-Aided-Diagnosis systems aiming at characterization are&#xD;
      called CADx.&#xD;
&#xD;
      Preliminary data on CADx showed a high feasibility and accuracy of AI for optical diagnosis&#xD;
      of colorectal polyp [6,7], and initial experiences in clinical practice confirmed preliminary&#xD;
      results [8].&#xD;
&#xD;
      To assess the potential benefit and risk of AI-assisted optical diagnosis with standard&#xD;
      colonoscopy, we exploited two new Computer-Aided-Diagnosis systems (CAD-EYE® Fujifilm Co.,&#xD;
      and GI-Genius® Medtronic) that provide the endoscopist with a real-time polyp&#xD;
      characterization without the need of optical magnification.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AI-assisted optical diagnosis performance</measure>
    <time_frame>6 Months</time_frame>
    <description>AI-assisted optical diagnosis performance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AI alone optical diagnosis performance</measure>
    <time_frame>6 Months</time_frame>
    <description>AI alone optical diagnosis performance</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Artificial Intelligence</condition>
  <arm_group>
    <arm_group_label>CAD-A</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CAD-B</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial Intelligence</intervention_name>
    <description>Artificial Intelligence</description>
    <arm_group_label>CAD-A</arm_group_label>
    <arm_group_label>CAD-B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients aged 40 or older undergoing a colonoscopy for gastrointestinal symptoms, fecal&#xD;
        immunohistochemical test positivity, primary screening or post-polypectomy surveillance.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - All patients aged 40 or older undergoing a colonoscopy for gastrointestinal symptoms,&#xD;
        fecal immunohistochemical test positivity, primary screening or post-polypectomy&#xD;
        surveillance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects with personal history of CRC, or IBD.&#xD;
&#xD;
          -  Subjects affected with Lynch syndrome or Familiar Adenomatous Polyposis.&#xD;
&#xD;
          -  patients with inadequate bowel preparation (defined as Boston Bowel Preparation Scale&#xD;
             &lt; 2 in any colonic segment).&#xD;
&#xD;
          -  patients with previous colonic resection.&#xD;
&#xD;
          -  patients on antithrombotic therapy, precluding polyp resection.&#xD;
&#xD;
          -  patients who were not able or refused to give informed written consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alessandro Repici, MD</last_name>
    <phone>0039-02-82247493</phone>
    <email>alessandro.repici@humanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

